Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115; and.
Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.
J Immunol. 2018 Apr 15;200(8):2757-2766. doi: 10.4049/jimmunol.1602090. Epub 2018 Mar 9.
Specialized proresolving mediators (SPMs) decrease NF-κB activity to prevent excessive tissue damage and promote the resolution of acute inflammation. Mechanisms for NF-κB regulation by SPMs remain to be determined. In this study, after LPS challenge, the SPMs 15-epi-lipoxin A (15-epi-LXA), resolvin D1, resolvin D2, resolvin D3, and 17-epi-resolvin D1 were produced in vivo in murine lungs. In LPS-activated human bronchial epithelial cells, select SPMs increased expression of the NF-κB regulators A20 and single Ig IL-1R-related molecule (SIGIRR). Of interest, 15-epi-LXA induced and in an lipoxin A receptor/formyl peptide receptor 2 (ALX/FPR2) receptor-dependent manner in epithelial cells and in murine pneumonia. This SPM regulated NF-κB-induced cytokines to decrease pathogen-mediated inflammation. In addition to dampening lung inflammation, surprisingly, 15-epi-LXA also enhanced pathogen clearance with increased antimicrobial peptide expression. Taken together, to our knowledge these results are the first to identify endogenous agonists for A20 and SIGIRR expression to regulate NF-κB activity and to establish mechanisms for NF-κB regulation by SPMs for pneumonia resolution.
特异性促解决介质 (SPM) 可降低 NF-κB 的活性,以防止过度的组织损伤并促进急性炎症的消退。SPM 调节 NF-κB 的机制仍有待确定。在这项研究中,在 LPS 挑战后,SPM 15-epi-脂氧素 A (15-epi-LXA)、解析素 D1、解析素 D2、解析素 D3 和 17-epi-解析素 D1 在小鼠肺部体内产生。在 LPS 激活的人支气管上皮细胞中,选择的 SPM 增加了 NF-κB 调节剂 A20 和单免疫球蛋白 IL-1R 相关分子 (SIGIRR) 的表达。有趣的是,15-epi-LXA 以脂氧素 A 受体/甲酰肽受体 2 (ALX/FPR2) 受体依赖的方式诱导 和 在上皮细胞和小鼠肺炎中。这种 SPM 调节 NF-κB 诱导的细胞因子以减少病原体介导的炎症。除了抑制肺部炎症外,令人惊讶的是,15-epi-LXA 还通过增加抗菌肽的表达增强了病原体的清除。总之,据我们所知,这些结果首次确定了 A20 和 SIGIRR 表达的内源性激动剂,以调节 NF-κB 活性,并为 SPM 调节肺炎消退的 NF-κB 建立机制。